Literature DB >> 10930690

Catalase immunization from Pseudomonas aeruginosa enhances bacterial clearance in the rat lung.

L D Thomas1, M L Dunkley, R Moore, S Reynolds, D A Bastin, J M Kyd, A W Cripps.   

Abstract

Pseudomonas aeruginosa is a common cause of infection in immunocompromised patients and is the major contributor to morbidity in individuals with cystic fibrosis (CF). The antibiotic resistance shown by this pathogen and morbidity in patients with chronic infection has encouraged investigations into the development of a vaccine. This study reports the purification of a 60 kDa protein, isolated from a mucoid strain of P. aeruginosa, identified by amino acid sequence analysis as the catalase protein (KatA). A rat model of acute P. aeruginosa respiratory infection was used to investigate the immunogenicity of KatA and determine the potential of mucosal immunization with KatA to protect against infection. Immunization regimens compared a single intra-Peyer's patch (IPP) immunization with an IPP primary inoculation followed by an intratracheal boost to the lungs. Mucosal immunization with KatA resulted in significant pulmonary clearance of both homologous (p<0.001) and heterologous (p<0.05) strains of P. aeruginosa. Both immunization regimens enhanced bacterial clearance, increased the rate of recruitment of phagocytes to the bronchoalveoli and induced KatA-specific antibody. However, the regimen that included a boost induced a more effective immune response that also resulted in better clearance of P. aeruginosa from the lungs. Mucosal immunization induced KatA- specific antibodies in the serum and the bronchoalveolar lavage, and KatA-specific lymphocyte proliferation in vitro in cells isolated from the mesenteric lymph nodes of immunized rats. The data presented suggests that KatA has the potential to afford a protective immune response against pulmonary infection by P. aeruginosa

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10930690     DOI: 10.1016/s0264-410x(00)00146-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Protection against pulmonary infection with Pseudomonas aeruginosa following immunization with P. aeruginosa-pulsed dendritic cells.

Authors:  S Worgall; T Kikuchi; R Singh; K Martushova; L Lande; R G Crystal
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

2.  Immunological response to parenteral vaccination with recombinant hepatitis B virus surface antigen virus-like particles expressing Helicobacter pylori KatA epitopes in a murine H. pylori challenge model.

Authors:  Michael Kotiw; Megan Johnson; Manisha Pandey; Scott Fry; Stuart L Hazell; Hans J Netter; Michael F Good; Colleen Olive
Journal:  Clin Vaccine Immunol       Date:  2011-12-28

Review 3.  Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface.

Authors:  Sankalp Malhotra; Don Hayes; Daniel J Wozniak
Journal:  Clin Microbiol Rev       Date:  2019-05-29       Impact factor: 26.132

4.  Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model.

Authors:  Antonio DiGiandomenico; Jayasimha Rao; Joanna B Goldberg
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

5.  Cloning and characterization of the gene coding for NADPH-sulfite reductase hemoprotein from Actinobacillus pleuropneumoniae and use of the protein product as a vaccine.

Authors:  P J Willson; G F Gerlach; S Klashinsky; A A Potter
Journal:  Can J Vet Res       Date:  2001-10       Impact factor: 1.310

6.  Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection.

Authors:  Ryka Moore; Jennelle M Kyd; Rosemary Carzino; Davide Armstrong; Keith Grimwood; Diana C Otczyk; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

Review 7.  Understanding Pseudomonas aeruginosa-Host Interactions: The Ongoing Quest for an Efficacious Vaccine.

Authors:  Maite Sainz-Mejías; Irene Jurado-Martín; Siobhán McClean
Journal:  Cells       Date:  2020-12-05       Impact factor: 6.600

Review 8.  Vaccination against respiratory Pseudomonas aeruginosa infection.

Authors:  Keith Grimwood; Jennelle M Kyd; Suzzanne J Owen; Helen M Massa; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.